These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. Friedland GH; Pollard R; Griffith B; Hughes M; Morse G; Bassett R; Freimuth W; Demeter L; Connick E; Nevin T; Hirsch M; Fischl M J Acquir Immune Defic Syndr; 1999 Aug; 21(4):281-92. PubMed ID: 10428106 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Chong KT; Pagano PJ Antiviral Res; 1997 Mar; 34(1):51-63. PubMed ID: 9107385 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. Ferry JJ; Herman BD; Carel BJ; Carlson GF; Batts DH J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):252-9. PubMed ID: 9665503 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559 [TBL] [Abstract][Full Text] [Related]
11. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration. Mascolini M AIDS Treat News; 1996 Dec; (No 260):3-5. PubMed ID: 11364022 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416 [TBL] [Abstract][Full Text] [Related]
13. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Wang LH; Chittick GE; McDowell JA Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227 [TBL] [Abstract][Full Text] [Related]
14. Effects of didanosine formulations on the pharmacokinetics of amprenavir. Shelton MJ; Giovanniello AA; Cloen D; Berenson CS; Keil K; DiFrancesco R; Hewitt RG Pharmacotherapy; 2003 Jul; 23(7):835-42. PubMed ID: 12885096 [TBL] [Abstract][Full Text] [Related]
15. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Shelton MJ; Adams JM; Hewitt RG; Steinwandel C; DeRemer M; Cousins S; Morse GD Pharmacotherapy; 1997; 17(3):438-44. PubMed ID: 9165548 [TBL] [Abstract][Full Text] [Related]
16. [A new AIDS drug in evaluation]. Fortschr Med; 1993 Aug; 111(24):12. PubMed ID: 7691696 [No Abstract] [Full Text] [Related]
18. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Chang M; Sood VK; Wilson GJ; Kloosterman DA; Sanders PE; Hauer MJ; Fagerness PE Drug Metab Dispos; 1997 Feb; 25(2):228-42. PubMed ID: 9029054 [TBL] [Abstract][Full Text] [Related]
19. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients. Jung D; Griffy K; Dorr A; Raschke R; Tarnowski TL; Hulse J; Kates RE J Clin Pharmacol; 1998 Nov; 38(11):1057-62. PubMed ID: 9824788 [TBL] [Abstract][Full Text] [Related]
20. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Borin MT; Cox SR; Herman BD; Carel BJ; Anderson RD; Freimuth WW Antimicrob Agents Chemother; 1997 Sep; 41(9):1892-7. PubMed ID: 9303380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]